Results 31 to 40 of about 15,859 (208)

Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma

open access: yesFrontiers in Oncology, 2023
Oligometastatic progression represents a unique manifestation of tumor immune-escape that can lead to disease progression during treatment with immune checkpoint inhibitor (ICI). The diagnosis and further optimal management of oligometastatic progression
Karam Khaddour   +4 more
doaj   +1 more source

Defining oligometastatic non-small cell lung cancer [PDF]

open access: yes, 2021
Objective: In this review, the concept of (synchronous) oligometastatic disease in patients with non-oncogene-driven non-small cell lung cancer (NSCLC) will be placed in the context of tumor biology and metastatic growth patterns.
A.C. (Anne-Marie) Dingemans   +23 more
core   +1 more source

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

open access: yesFrontiers in Oncology, 2022
The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors to endocrine therapy has remarkably improved the outcome of patients affected with hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2 ...
Andrea Botticelli   +19 more
doaj   +1 more source

Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors

open access: yesFrontiers in Oncology, 2020
BackgroundLocal ablative treatments improve survival in patients with oligometastatic disease in addition to chemotherapy. The application of immune checkpoint inhibitors prolonged patients’ survival in different tumor entities.
Philipp Schubert   +26 more
doaj   +1 more source

Risk factors and management of oligometastatic non-small cell lung cancer

open access: yesTherapeutic Advances in Respiratory Disease, 2016
Non-small cell lung cancer (NSCLC) is an aggressive malignancy with close to half of all patients presenting with metastatic disease. A proportion of these patients with limited metastatic disease, termed oligometastatic disease, have been shown to ...
Akshar N. Patel   +2 more
doaj   +1 more source

SABR in oligometastatic breast cancer: Current status and future directions [PDF]

open access: yes, 2021
Oligometastatic breast cancer (OMBC) is a heterogeneous disease with intrinsic biological diversity. It is increasingly accepted in clinical practice that patients with OMBC could be treated with the expectation of long-term disease remission.
Siva, S   +5 more
core   +1 more source

The oligometastatic paradigm and the role of radiotherapy

open access: yesClinical Medicine, 2023
Most cancer-related deaths are due to metastatic disease. There is now an emerging evidence base suggesting that a subgroup of metastatic patients benefit significantly from local resection (surgery) or ablation (stereotactic ablative body radiation, SABR) of their metastatic sites. These patients are in what has been termed the 'oligometastatic state',
Nugent, Killian, Good, James
openaire   +2 more sources

Surgical treatment of oligometastatic nasopharyngeal carcinoma

open access: yesClinical Surgical Oncology, 2023
Oligometastasis-directed therapies have shown promise in improving patient outcomes. In this review, we summarized the current understanding of oligometastatic nasopharyngeal carcinoma (NPC) and the role of surgery in its management.
Wendan Gong   +3 more
doaj   +1 more source

Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update

open access: yes, 2022
Oligometastatic non-small-cell lung cancer (NSCLC) is a distinct entity that is different from localized and disseminated diseases. The definition of oligometastatic NSCLC varies across studies in past decades owing to the use of different imaging ...
Ue-Cheung Ho, Yi-Hsing Chen, Lu-Ting Kuo
core   +1 more source

Surgical approach in the oligometastatic patient [PDF]

open access: yesAnnals of Translational Medicine, 2018
In the setting of a stage IV non-small cell lung cancer (NSCLC), oligometastatic patients represent a heterogeneous group whose incidence is increasing as far as with the adoption of new therapeutic regimens, the improvement of the molecular characterization assays and the increasing number of long-survivor patients. The oligometastatic state undergone
Divisi D.   +4 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy